key: cord-0905776-5fif117n authors: Varma, Niraj; Marrouche, Nassir F.; Aguinaga, Luis; Albert, Christine M.; Arbelo, Elena; Choi, Jong‐Il; Chung, Mina K.; Conte, Giulio; Dagher, Lilas; Epstein, Laurence M.; Ghanbari, Hamid; Han, Janet K.; Heidbuchel, Hein; Huang, He; Lakkireddy, Dhanunjaya R.; Ngarmukos, Tachapong; Russo, Andrea M.; Saad, Eduardo B.; Saenz Morales, Luis C.; Sandau, Kristin E.; Raghav M. Sridhar, Arun; Stecker, Eric C.; Varosy, Paul D.; Rhythm, Heart title: HRS/EHRA/APHRS/LAHRS/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic date: 2020-06-25 journal: J Arrhythm DOI: 10.1002/joa3.12389 sha: 681ee09d9fce10a8deac25d1d94a03b9996f61d2 doc_id: 905776 cord_uid: 5fif117n Coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), started in the city of Wuhan late in 2019. Within a few months, the disease spread toward all parts of the world and was declared a pandemic on March 11, 2020. The current health care dilemma worldwide is how to sustain the capacity for quality services not only for those suffering from COVID‐19 but also for non‐COVID‐19 patients, all while protecting physicians, nurses, and other allied health care workers. Coronavirus disease 2019 , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), started in the city of Wuhan late in 2019. Within a few months, the disease spread toward all parts of the world and was declared a pandemic on March 11, 2020 . The current health care dilemma worldwide is how to sustain the capacity for quality services not only for those suffering from COVID-19 but also for non-COVID-19 patients, all while protecting physicians, nurses, and other allied health care workers. The pandemic poses challenges to electrophysiologists at several levels. Hospitalized COVID-19-positive patients may have preexisting arrhythmias, develop new arrhythmias, or be placed at increased arrhythmic risk from therapies for COVID-19. Cardiac arrhythmia incidence in hospitalized patients has been documented in a few published studies, with reported rates of 7.9% 1 infection. 3 There have also been several case reports of atrioventricular block in hospitalized patients, which is otherwise rarely described during viral illness. 4, 5 Although the residual left ventricular dysfunction and arrhythmic risk are currently unknown, preliminary pathophysiological, 6 histological, 7 and imaging 8 data suggest that SARS-CoV-2 infection holds the potential to induce durable myocardial changes predisposing to arrhythmias or heart failure. Electrocardiographic monitoring and inpatient monitoring services may become necessary but face the potential hurdles of limited telemetry wards, contamination of equipment and infection of health care personnel, and shortage of personal protective equipment. 9, 10 In parallel, there is a continued responsibility to maintain care of COVID-19-negative patients with arrhythmias. These pressures have led to inventive utilization and adaptation of existing telemedicine technologies as alternative options. This document discusses how digital health may facilitate electrophysiology practice for patients with arrhythmia, whether hospitalized for COVID-19 or not. The representation of authors from some of the most severely affected countries, such as China, Spain, Italy, and the United States, is a tribute from our worldwide community to those colleagues who have worked on the front lines of the pandemic. This article is protected by copyright. All rights reserved In light of the current pandemic, monitoring strategies should focus on selecting high-risk patients in need of close surveillance and using alternative remote recording devices to preserve personal protective equipment and protect health care workers from potential contagious harm. For inpatient monitoring, telemetry is reasonable when there is concern for clinical deterioration (as may be indicated by acute illness, vital signs, or sinus tachycardia), or in patients with cardiovascular risk factors and/or receiving essential QT-prolonging medications. Telemetry is generally not necessary for persons under investigation without concern for arrhythmias or clinical deterioration and in those not receiving QTprolonging drug therapy. In situations in which a hospital's existing telemetry capacity has been exceeded by patient numbers or when conventional telemetry monitoring is not feasible, such as off-site or nontraditional hospital units, mobile devices may be used, for example, mobile cardiac outpatient telemetry (MCT) as an adjunctive approach to support inpatient care. [11] [12] [13] [14] [15] The majority of MCT devices can provide continuous arrhythmia monitoring using a single-lead electrocardiogram (ECG) and allow for real-time and offline analysis of long-term ECG data. Telemetry can be extended using patch monitoring. 16, 17 Smartphone ECG monitors are wireless and have also been utilized during the current pandemic. Information is limited, however, on how parameters such as QTc measured on a single-(or limited number) lead ECG can reliably substitute for 12lead ECG information. 18, 19 In one study, QT was underestimated by smartphone single-lead ECG. 20 The principles of remote patient management, crossing geographic, social, and cultural barriers, can be extended to outpatient care and are important to maintain continuity of care for non-COVID-19 patients. [21] [22] [23] Virtual clinics move far beyond simple telephone contacts by integrating information from photos, video, mobile heart rhythm and mobile health devices recording ECG, and remote cardiovascular implantable electronic device (CIED) interrogations. 24 A variety of platforms have been developed and used specifically to provide telehealth to patients via video teleconferencing 25, 26 (Table 1) . Most health care centers have expanded use of telemedicine, with some reporting 100% transformation of in-person clinic visits to telemedicine-based visits in order to maintain care for non-COVID-19 patients, thus obviating their need to This article is protected by copyright. All rights reserved come to the hospital or clinic. This supplements social distancing measures and reduces the risk of transmission, especially for the older and more vulnerable populations. It also becomes a measure to control intake into emergency rooms and outpatient facilities and to permit rapid access when necessary to subspecialists. Electrophysiology is well placed for virtual consultations. All preobtained data, including ECGs, ambulatory ECG monitoring, cardiac imaging, and coronary angiography can be adequately reviewed electronically. Digital tools such as direct-to-consumer mobile ECG ( Table 2 ) and wireless blood pressure devices can be used to further complement the telehealth visit without in-person contact. CIED, wearable/mobile health, and clinical data can be integrated into clinician workflow. Administration; HCQ = hydroxychloroquine; HR = heart rate; HRV = heart rate variability; RR = respiratory rate. This article is protected by copyright. All rights reserved No specific cure exists for COVID-19. [28] [29] [30] Potential COVID-19 therapies, especially hydroxychloroquine and azithromycin, are being investigated in ongoing trials but also have been used off label in many parts of the world. These may exert QT-prolonging effects 31 (Table 3 ) and, since recent observational data have questioned their efficacy, require a careful risk-benefit adjudication. 32 Combination therapy (eg, hydroxychloroquine and azithromycin) may have synergistic effects on QT prolongation. 33, 34 In a retrospective cohort study of 1,438 COVID-19 patients hospitalized in metropolitan New York (ie, a disease epicenter), cardiac arrest was more frequent in patients who received hydroxychloroquine with azithromycin compared with patients who received neither drug. 35 The adjusted hazard ratio for in-hospital mortality for treatment with hydroxychloroquine alone was 1.08, for azithromycin alone was 0.56, and for combined hydroxychloroquine and azithromycin was 1.35. However, none of these hazard ratios were statistically This article is protected by copyright. All rights reserved significant. The observational design of this study may limit interpretation of these findings. In the absence of clear efficacy data, treatment options should be individualized taking into account their proarrhythmic potential for torsade de pointes, which may be enhanced by concomitant administration of other QTprolonging drugs (eg, antiarrhythmics, psychotropics, etc). In COVID-19 patients receiving prior antiarrhythmic therapy, there should be a thorough consideration of risk vs benefit before initiating any QT-prolonging COVID-19 therapies, especially considering their unproven value. For instance, although some recent observational studies highlight adverse effects of hydroxychloroquine in treating this infectious disease, its use is likely to persist outside of randomized trials because of its affordability and global availability compared with, for example, remdesivir. 35 If one of these drugs is judged to be critical, monitoring should be initiated. If life-threatening arrhythmias (VT/VF) occur, the benefit of antiarrhythmic drugs, notably amiodarone, outweighs the potential harm of hydroxychloroquine or This article is protected by copyright. All rights reserved other QT-prolonging drugs targeting COVID-19, and in these cases antiarrhythmic drugs should be prioritized and used as deemed necessary. Most importantly, all modifiable predisposing factors for QTc prolongation (electrolyte disturbances, drug-to-drug interaction) that may enhance arrhythmia susceptibility should be corrected, and the small subset of individuals with an underlying genetic predisposition such as congenital long QT syndrome (in whom QTc-prolonging medications are contraindicated) should be identified. Additionally, caution must be exercised in case of subclinical or manifest myocarditis that may increase the vulnerability to proarrhythmias associated with QT-prolonging drugs. If drugs that exert a QT-prolonging effect are to be initiated in an inpatient setting, a baseline 12-lead ECG should be acquired. This article is protected by copyright. All rights reserved Several double-and multi-arm blind randomized controlled trials are underway worldwide for COVID-19 outpatients utilizing different medications that may prolong the QT interval. 52-56 These drugs are being tested either alone or in various combinations and are being compared with one another, with differential dosing regimens and/or placebo. These drugs are also being tested for postexposure prophylaxis in high-risk groups. Mobile health using smartphone-based portable ECG devices as QTc monitoring tools is an innovative and economical solution to conduct monitoring in outpatient trials. For instance, in one trial evaluating hydroxychloroquine and azithromycin (hydroxychloroquine alone and hydroxychloroquine/azithromycin combination) against a placebo, participants receive remote training to acquire a 6-lead ECG at baseline and then at specified follow-up intervals through the trial period (Figure 1) . These ECGs are transmitted to a remote QTc monitoring site, where the QTc is assessed and monitored over the treatment period. The COVID-19 public health emergency has forced changes to traditional norms of health care access and delivery across all continents. 10 It has accelerated adoption of telemedicine and all aspects of digital health, regarded as a positive development. Today's new reality will likely define medicine going forward. Many This article is protected by copyright. All rights reserved monitoring and diagnostic testing aspects of both inpatient and outpatient care will be increasingly served by digital medicine tools. The need for contactless monitoring for inpatients triaged to intensive care unit, telemetry, or nonconventional environments, as well as for outpatients needing continued management, has triggered novel implementation of digital health monitoring tools. Some centers have created algorithms based on predictive analytics of electronic medical record (EMR) data. Centralized monitoring or mobile continuous monitoring has improved patient outcomes, reduced manpower needs, and is being utilized more commonly. 57 The use of wearables such as watches, smartphones, and smart beds (with elimination of cables and skin electrodes) for in-hospital telemetry is a novel approach. This type of wireless monitoring may be continued after discharge, permitting prolonged surveillance of rhythm and other physiological parameters. 12 Bracelet technologies may transmit multiple parameters (eg, heart rate, sleep, oxygen desaturation index, blood pressure) via a smartphone link to centralized hubs. These technologies provide a solution for intensive monitoring extending beyond the hospital environment. Outpatient management has been revolutionized since the start of the pandemic. Social distancing measures and restricted clinic access have driven the rapid adoption of telehealth mechanisms to continue management of non-COVID-19 patients. Virtual visits that have been used for decades to reach isolated communities, 58 but less commonly utilized in advanced health systems, have now become the mainstay of ambulatory care across all subspecialties. The initial experience appears to have been positive for both patient and caregiver. Heart rhythm professionals are fortunate to have a choice of wireless technologies to relay monitored information to maintain connection. 12 Wearable and smartphone-based devices allow convenient real-time monitoring for arrhythmias on a long-term basis due to the comfort associated with their small size and ease of use while reducing patient and health care worker exposure. Remote CIED monitoring has existed for decades. 24 It is strongly endorsed by professional societies, but in practice only a fraction of its diagnostic and therapeutic capabilities has been utilized-until now. 59 Since the start of the pandemic, utilization of wireless communication with CIEDs has grown exponentially, permanently altering the future of device follow-up. Patient outcomes may be improved with intensive device-based monitoring compared with traditional in-clinic evaluations at regular intervals. 60 Recent data indicate that in-person CIED evaluation can be extended safely to at least biennially when daily digital connectivity is maintained. 61 Remote monitoring has the potential advantage of detecting and alerting caregivers (and in the future- In summary, the crisis precipitated by the pandemic has catalyzed the adoption of remote patient management across many specialties and for heart rhythm professionals, in particular. This practice is here to stay-it will persist even if other less arrhythmogenic treatment strategies evolve for COVID-19 and after the pandemic has passed. This is an opportunity to embed and grow remote services in everyday medical practice worldwide. This article is protected by copyright. All rights reserved Clinical characteristics of Covid-19 in New York City Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) Transient complete heart block in a patient with critical COVID-19 A young woman presenting with a viral prodrome, palpitations, dizziness, and heart block Cardiac and arrhythmic complications in patients with COVID-19 Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19) Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: a statement from the Canadian Heart Rhythm Society How to protect the protectors: 10 lessons to learn for doctors fighting the COVID-19 coronavirus Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry Comparison of QT interval readings in normal sinus rhythm between a smartphone heart monitor and a 12-lead ECG for healthy volunteers and inpatients receiving sotalol or dofetilide A wearable remote monitoring system for the identification of subjects with a prolonged QT interval or at risk for drug-induced long QT syndrome Can smartphone wireless ECGs be used to accurately assess ECG intervals in pediatrics? A comparison of mobile health monitoring to standard 12-lead ECG Accepted Article This article is protected by copyright. All rights reserved 16. US Food & Drug Administration COVID-19 Comparison of 2 methods of measuring the QT interval Bedside monitoring of the QT interval Kardia Mobile applicability in clinical practice: a comparison of Kardia Mobile and standard 12-lead electrocardiogram records in 100 consecutive patients of a tertiary cardiovascular care center Telemedicine: potential applications in epidemic situations Virtually perfect? Telemedicine for Covid-19 Online mental health services in China during the COVID-19 outbreak Telemedicine and cardiac implants: what is the benefit? Information governance it-systems-and-services/approved-econsultation-systems Procurement of pre-approved suppliers of online and video consultation systems for GP practices to support COVID-19 Compassionate use of remdesivir for patients with severe Covid-19 European Society of Cardiology. ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review Observational study of hydroxychloroquine in hospitalized patients with Covid-19 QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state COVID-19 experimental therapies and TdP risk Assessment of multi-ion channel block in a phase I randomized study design: results of the CiPA phase I ECG biomarker validation study Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers The cardiac safety of chloroquine phosphate treatment in patients with systemic lupus erythematosus: the influence on arrhythmia, heart rate variability and repolarization parameters Cardiac damage from chronic use of chloroquine: a case report and review of the literature Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus Electrophysiologic studies on the risks and potential mechanism underlying the proarrhythmic nature of azithromycin Risk evaluation of azithromycin-induced QT prolongation in real-world practice ZITHROMAX (azithromycin) for IV infusion only. Highlights of prescribing information Azithromycin and the risk of cardiovascular death Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System The role of macrolide antibiotics in increasing cardiovascular risk Azithromycin and the risk of cardiovascular complications This article is protected by copyright. All rights reserved